Wall Street brokerages expect DURECT Co. (NASDAQ:DRRX) to report ($0.03) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for DURECT’s earnings, with estimates ranging from ($0.05) to ($0.02). DURECT reported earnings per share of $0.04 during the same quarter last year, which would indicate a negative year over year growth rate of 175%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 7th.

According to Zacks, analysts expect that DURECT will report full year earnings of ($0.19) per share for the current financial year, with EPS estimates ranging from ($0.20) to ($0.17). For the next year, analysts anticipate that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.22) to ($0.12). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow DURECT.

DURECT (NASDAQ:DRRX) last posted its quarterly earnings results on Wednesday, August 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.83 million. DURECT had a negative net margin of 2.04% and a negative return on equity of 4.27%.

Several analysts have weighed in on DRRX shares. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of DURECT in a research note on Tuesday, July 31st. BidaskClub lowered shares of DURECT from a “hold” rating to a “sell” rating in a research note on Wednesday, June 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. DURECT presently has an average rating of “Hold” and an average target price of $2.50.

DRRX stock opened at $0.97 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.60 and a quick ratio of 3.36. DURECT has a 1-year low of $0.75 and a 1-year high of $2.55. The firm has a market cap of $178.20 million, a price-to-earnings ratio of -32.33 and a beta of 0.88.

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC increased its stake in DURECT by 235.1% during the first quarter. Jane Street Group LLC now owns 48,827 shares of the specialty pharmaceutical company’s stock valued at $104,000 after purchasing an additional 34,255 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in DURECT in the first quarter worth about $131,000. MetLife Investment Advisors LLC acquired a new stake in DURECT in the first quarter worth about $158,000. Alps Advisors Inc. acquired a new stake in DURECT in the second quarter worth about $366,000. Finally, Mackay Shields LLC lifted its holdings in DURECT by 45.3% in the second quarter. Mackay Shields LLC now owns 249,100 shares of the specialty pharmaceutical company’s stock worth $389,000 after purchasing an additional 77,700 shares during the period. Hedge funds and other institutional investors own 47.80% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand.

Recommended Story: Trading Strategy

Get a free copy of the Zacks research report on DURECT (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.